KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) Research & Development (2016 - 2025)

Exact Sciences (EXAS) has disclosed Research & Development for 16 consecutive years, with $191.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 95.99% to $191.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $523.0 million through Dec 2025, up 21.29% year-over-year, with the annual reading at $523.0 million for FY2025, 21.29% up from the prior year.
  • Research & Development for Q4 2025 was $191.5 million at Exact Sciences, up from $117.3 million in the prior quarter.
  • The five-year high for Research & Development was $191.5 million in Q4 2025, with the low at $75.4 million in Q3 2021.
  • Average Research & Development over 5 years is $108.0 million, with a median of $105.7 million recorded in 2022.
  • Peak annual rise in Research & Development hit 225.15% in 2021, while the deepest fall reached 80.18% in 2021.
  • Over 5 years, Research & Development stood at $88.5 million in 2021, then increased by 7.41% to $95.0 million in 2022, then grew by 21.19% to $115.2 million in 2023, then dropped by 15.17% to $97.7 million in 2024, then skyrocketed by 95.99% to $191.5 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $191.5 million, $117.3 million, and $108.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.